[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hormone-Sensitive Prostate Cancer Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 46 pages | ID: H75AA070C8AEN
VPAResearch

US$ 630.00 US$ 700.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Hormone-Sensitive Prostate Cancer ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Hormone-Sensitive Prostate Cancer disease clinical trials. The research work analyzes the ongoing Hormone-Sensitive Prostate Cancer clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Hormone-Sensitive Prostate Cancer treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Hormone-Sensitive Prostate Cancer clinical trials.

Scope of the Report-
  • Ongoing Hormone-Sensitive Prostate Cancer clinical trials across regions
  • Trial information by Phase and Subjects recruited
  • Trial information by status, type, sponsor type
  • Drugs used for treatment of Hormone-Sensitive Prostate Cancer
  • Both observational and interventional trials analyzed
  • Leading companies and universities participating in Hormone-Sensitive Prostate Cancer clinical trials
Reasons to Buy
  • Track competition and design competitive advantages
  • Identify right partners to associate with for further research
  • Evaluate potential opportunities available in further clinical trials of the disease
  • Formulate business development strategies through success rates of clinical trials
  • Identify quick markets for recruiting subjects based on trials count by each market
1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Hormone-Sensitive Prostate Cancer Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Hormone-Sensitive Prostate Cancer Trials by Phase
3.2 Ongoing Hormone-Sensitive Prostate Cancer Trials by Type
3.3 Ongoing Hormone-Sensitive Prostate Cancer Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Hormone-Sensitive Prostate Cancer Trials
4.2 Top 10 Countries conducting Hormone-Sensitive Prostate Cancer Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Hormone-Sensitive Prostate Cancer Trials by Sponsor Type
5.2 Hormone-Sensitive Prostate Cancer Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Hormone-Sensitive Prostate Cancer Trials by year
6.2 Subjects Recruited for Hormone-Sensitive Prostate Cancer Trials by Phase
6.3 Subjects Recruited for Hormone-Sensitive Prostate Cancer Trials by Trial Type
6.4 Subjects Recruited for Hormone-Sensitive Prostate Cancer Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Hormone-Sensitive Prostate Cancer Trials- Phase
7.2 Ongoing Hormone-Sensitive Prostate Cancer Trials- Phase
7.3 Ongoing Hormone-Sensitive Prostate Cancer Trials- Phase
7.4 Ongoing Hormone-Sensitive Prostate Cancer Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

LIST OF FIGURES

Figure 1: Hormone-Sensitive Prostate Cancer- Clinical Trials by Country
Figure 2: Hormone-Sensitive Prostate Cancer- Clinical Trials by Phase of Development, 2018
Figure 3: Hormone-Sensitive Prostate Cancer- Clinical Trials by Status, 2018
Figure 4: Hormone-Sensitive Prostate Cancer- Clinical Trials by Type, 2018
Figure 5: Hormone-Sensitive Prostate Cancer- Clinical Trials Split by Region, 2000-2018
Figure 6: Hormone-Sensitive Prostate Cancer- Clinical Trials by Type of Economy, 2018
Figure 7: Hormone-Sensitive Prostate Cancer- Enrolment by Phase, 2018
Figure 8: Hormone-Sensitive Prostate Cancer- Enrolment by Trial Type, 2018
Figure 9: Hormone-Sensitive Prostate Cancer- Enrolment by Recruitment Status, 2018
Figure 10: Hormone-Sensitive Prostate Cancer- Clinical Trials by Sponsor Type, 2018
Figure 11: Hormone-Sensitive Prostate Cancer- Enrolment by Type of Sponsors
Figure 12: Hormone-Sensitive Prostate Cancer- Enrolment by Leading Sponsors

LIST OF TABLES

Table 1: Hormone-Sensitive Prostate Cancer- Clinical Trials by Sponsor Type, 2018
Table 2: Hormone-Sensitive Prostate Cancer- Clinical Trials by Economy Type, 2018
Table 3: Hormone-Sensitive Prostate Cancer- Clinical Trials by Region, 2018
Table 4: Hormone-Sensitive Prostate Cancer- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Hormone-Sensitive Prostate Cancer- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Hormone-Sensitive Prostate Cancer- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Hormone-Sensitive Prostate Cancer- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Hormone-Sensitive Prostate Cancer- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Hormone-Sensitive Prostate Cancer- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company


More Publications